Lack of antiviral activity of darunavir against SARS-CoV-2

International Journal of Infectious Diseases

Volumn 97, Issue , 2020, Pages 7-10

  De Meyer, Sandra ^a   Bojkova, Denisa ^b   Cinatl, Jindrich ^b   Van Damme, Ellen ^a   Buyck, Christophe ^a   Van Loock, Marnix ^a   Woodfall, Brian ^c   Ciesek, Sandra ^b,d  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Current address: Janssen Biopharma   (United States)

^d German Centre for Infection Research (DZIF)   (Germany)

Author keywords

COVID 19; Darunavir; In vitro; SARS CoV 2

Indexed keywords

ANTIRETROVIRUS AGENT; COBICISTAT PLUS DARUNAVIR; REMDESIVIR; ANTIVIRUS AGENT; DARUNAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DRUG BLOOD LEVEL; DRUG SAFETY; EC50; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS ISOLATION; BETACORONAVIRUS; CELL LINE; CELL SURVIVAL; CORONAVIRUS INFECTION; DRUG EFFECT; PANDEMIC; VIRUS PNEUMONIA;

ANTIVIRAL AGENTS; BETACORONAVIRUS; CELL LINE; CELL SURVIVAL; CORONAVIRUS INFECTIONS; DARUNAVIR; HUMANS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85086363374     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2020.05.085     Document Type: Article

References (21)

1. Baden, L.R., Rubin, E.J., Covid-19 — the search for effective therapy. N Engl J Med 382:19 (2020), 1851–1852, 10.1056/NEJMe2005477.
2. Bojkova, D., Klann, K., Koch, B., Widera, M., Krause, D., Ciesek, S., et al. SARS-CoV-2 infected host cell proteomics reveal potential therapy targets, [Under review]. Nature, 2020 Preprint available at: https://www.researchsquare.com/article/rs-17218/v1.
3. Cahn, P., Fourie, J., Grinsztejn, B., Hodder, S., Molina, J.M., Ruxrungtham, K., et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 25:7 (2011), 929–939, 10.1097/QAD.0b013e328345ee95.
4. Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:19 (2020), 1787–1799, 10.1056/NEJMoa2001282.
5. Chang Y-C, Tung Y-A, Lee K-H, Chen T-F, Hsiao Y-C, Chang H-C, et al. Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking. Preprints ( www.preprints.org) 2020. https://doi.org/10.20944/preprints202002.0242.v1.
6. Chu, C.M., Cheng, V.C., Hung, I.F., Wong, M.M., Chan, K.H., Chan, K.S., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:3 (2004), 252–256, 10.1136/thorax.2003.012658.
7. Farag, A., Wang, P., Ahmed, M., Sadek, H., Identification of FDA approved drugs targeting COVID-19 virus by structure-based drug repositioning. 2020 https://chemrxiv.org/articles/Identification_of_FDA_Approved_Drugs_Targeting_COVID-19_Virus_by_Structure-Based_Drug_Repositioning/12003930/1.
8. Haitao Y, Zihe R. 2020. Available at Shanghai Institute of Materia Medica. http://www.simm.ac.cn/xwzx/kydt/202001/t20200125_5494417.html.
9. Hoehl, S., Rabenau, H., Berger, A., Kortenbusch, M., Cinatl, J., Bojkova, D., et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med 382:13 (2020), 1278–1280, 10.1056/NEJMc2001899.
10. King, N.M., Prabu-Jeyabalan, M., Nalivaika, E.A., Wigerinck, P., de Béthune, M.P., Schiffer, C.A., Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 78:21 (2004), 12012–12021, 10.1128/JVI.78.21.12012-12021.2004.
11. Kruse, R.L., Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research, 9(January), 2020, 72, 10.12688/f1000research.22211.2.
12. Lu, R., Zhao, X., Juan, L., Niu, P., Yang, B., Wu, H., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:10224 (2020), 565–574 https/doi.org/10.1016S0140-6736(20)30251-8.
13. Navarro, J., Curran, A., Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS. HIV AIDS (Auckl) 8 (2016), 175–182, 10.2147/HIV.S56158.
14. Orkin, C., DeJesus, E., Khanlou, H., Stoehr, A., Supparatpinyo, K., Lathouwers, E., et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Med 14:1 (2013), 49–59, 10.1111/j.1468-1293.2012.
15. Prezcobix prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205395s001lbl.pdf. [Accessed 27 March 2020].
16. Rezolsta Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/rezolsta-epar-product-information_en.pdf. [Accessed 27 March 2020].
17. Sang, P., Tian, S., Meng, Z., Yang, L., Insight derived from molecular docking and molecular dynamics simulations into the binding interactions between HIV-1 protease inhibitors and SARS-CoV-2 3CLpro. ChemRxiv, 2020 Preprint. https://chemrxiv.org/articles/Insight_Derived_from_Molecular_Docking_and_Molecular_Dynamics_Simulations_into_the_Binding_Interactions_Between_HIV-1_Protease_Inhibitors_and_SARS-CoV-2_3CLpro/11932995/1.
18. Tashima, K., Crofoot, G., Tomaka, F.L., Kakuda, T.N., Brochot, A., Van de Casteele, T., et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther, 11, 2014, 39, 10.1186/1742-6405-11-39.
19. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:3 (2020), 269–271, 10.1038/s41422-020-0282-0.
20. Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 10:5 (2020), 766–788, 10.1016/j.apsb.2020.02.008.
21. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:8 (2020), 727–733, 10.1056/NEJMoa2001017.